You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T Cells

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mesothelin-positive Advanced Malignant Solid Tumors Trial (Anti-mesothelin CAR-T cells)

Not yet recruiting
  • Mesothelin-positive Advanced Malignant Solid Tumors
  • Anti-mesothelin CAR-T cells
  • (no location specified)
Mar 13, 2023

Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma Trial (GPC2 CAR T cells)

Not yet recruiting
  • Refractory Neuroblastoma
  • +2 more
  • GPC2 CAR T cells
  • (no location specified)
Dec 21, 2022

Multiple Myeloma, Immune System Diseases Trial in Chapel Hill (CAR138 T Cells)

Recruiting
  • Multiple Myeloma
  • Immune System Diseases
  • CAR138 T Cells
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jan 10, 2023

Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Lymphoma
  • CD70-targeting CAR-T cells
  • Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 9, 2023

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Duarte

Not yet recruiting
  • Castration-Resistant Prostate Carcinoma
  • +2 more
  • Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
  • +7 more
  • Duarte, California
    City of Hope Medical Center
Apr 5, 2023

Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +4 more
  • (no location specified)
Oct 23, 2023

Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Trial (TmPSMA-02 CAR T Cells)

Not yet recruiting
  • Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
  • TmPSMA-02 CAR T Cells
  • (no location specified)
Sep 13, 2023

Pancreas Cancer, CAR-T Cell Therapy, Mesothelin Trial in Guangzhou (CAR-T cells)

Recruiting
  • Pancreas Cancer
  • +3 more
  • CAR-T cells
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Mar 10, 2023

Sarcoma Trial in Houston (Autologous HER2-specific T cells, Fludarabine, Cyclophosphamide)

Active, not recruiting
  • Sarcoma
  • Autologous HER2-specific T cells
  • +3 more
  • Houston, Texas
  • +1 more
Nov 21, 2022

Hematologic Diseases Trial in Hefei (allogeneic ?9d2 T Cells, Fludarabine, Cyclophosphamide)

Recruiting
  • Hematologic Diseases
  • allogeneic γ9δ2 T Cells
  • +3 more
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Feb 23, 2023

Pancreatic Cancer Trial in Shatin (MSLN CART)

Not yet recruiting
  • Pancreatic Cancer
  • MSLN CART
  • Shatin, N.t., Hong Kong
    Endoscopy Centre, Prince of Wales Hospital
Sep 19, 2023

Solid Tumor Trial in Taichung (HLA-G-CAR.BiTE allogeneic ?d T cells)

Not yet recruiting
  • Solid Tumor
  • HLA-G-CAR.BiTE allogeneic γδ T cells
  • Taichung, Non-US, Taiwan
    China Medical University Hospital
Nov 27, 2023

Advanced Sarcoma Trial (NKG2D-CAR memory T cell)

Not yet recruiting
  • Advanced Sarcoma
  • NKG2D-CAR memory T cell
  • (no location specified)
Oct 17, 2023

Solid Tumor, Adult Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Solid Tumor, Adult
  • CD70-targeting CAR-T cells
  • Beijing, Iotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 8, 2023

HER2 Positive Advanced Solid Tumors Trial (HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide)

Not yet recruiting
  • HER2 Positive Advanced Solid Tumors
  • HypoSti.CAR-HER2 T cells
  • +2 more
  • (no location specified)
Jan 12, 2023

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

Recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Manufactured Anti-BCMA CAR-T cells
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jan 6, 2023

Advanced Solid Tumors Trial in Hangzhou (Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT))

Recruiting
  • Advanced Solid Tumors
  • Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)
  • Hangzhou, China
    First affiliated hospital, School of Medicine, Zhejiang Universi
Aug 3, 2023

EBV-positive Nasopharyngeal Carcinoma Trial in Guangzhou (Cohort A: 3.0x10^6 CAR-T cells/kg, Cohort B: 9.0x10^6CAR-T cells/kg,

Not yet recruiting
  • EBV-positive Nasopharyngeal Carcinoma
  • Cohort A: 3.0x10^6 CAR-T cells/kg
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 16, 2023

AML Trial in Beijing (IM23)

Completed
  • AML
  • Beijing, China
    Xian Lu
Jan 18, 2023

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in Seattle (Autologous Mesothelin-specific

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Stage IV Pancreatic Cancer AJCC v8
  • Autologous Mesothelin-specific TCR-T Cells
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 31, 2023

Leukemia, Acute Lymphoblastic Leukemia Trial in New York (gene-modified T cells targeted)

Active, not recruiting
  • Leukemia
  • Acute Lymphoblastic Leukemia
  • gene-modified T cells targeted
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 1, 2023

CNS Tumors, Atypical Teratoid/Rhabdoid Tumor, Diffuse Midline Glioma, H3 K27M-Mutant Trial in Memphis (B7-H3-CAR T cells)

Not yet recruiting
  • Central Nervous System Neoplasms
  • +6 more
  • B7-H3-CAR T cells
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Apr 18, 2023

T Cell Lymphoblastic Lymphoma Trial in Beijing (BT-007 CD7 CAR-T cells)

Recruiting
  • T Cell Lymphoblastic Lymphoma
  • BT-007 CD7 CAR-T cells
  • Beijing, China
    Beijing Cancer Hospital
Sep 22, 2022

B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 10, 2023